QT-019C
/ Xiniao Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 07, 2026
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
(clinicaltrials.gov)
- P1 | N=15 | Not yet recruiting | Sponsor: Tianjin Huanhu Hospital
New P1 trial • CNS Disorders • Immunology • Multiple Sclerosis • Myasthenia Gravis • Neuromyelitis Optica Spectrum Disorder • Rare Diseases
January 03, 2026
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China
New P1 trial • ANCA Vasculitis • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Myositis • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • Thrombocytopenia • Vasculitis
1 to 2
Of
2
Go to page
1